



Peanut Allergy


Panida Sriaroon, MD Professor of Pediatrics Director, Fellowship Program Medical Director, USF/All Children's Hospital Allergy/Immunology clinic Medical Director, JHACH Food Allergy Clinic

Learning Objectives

1 Describe natural history of peanut allergy

2 Select appropriate tools for diagnosing peanut allergy

- 3 Discuss treatment options for patients with peanut allergy
- 4 Assess outcomes of recent peanut allergy clinical trials



Increasing incidence and prevalence of food allergy diagnoses in active component US Armed Forces, 2000-2017

What Do We Know?

Increasing prevalence of FA 8% of children (<3 years)

Lee and Stahlman. JACI Pract 2020 Jan;8(1):361-363

If you could choose.....

Patient 1

D. farinae	* < 0.35
D. pteronyssinus	* < 0.35
📃 Bermuda Grass	* < 0.35
Peanut	* H 91.10
Cat Antigen	* < 0.35
Johnson Grass	* < 0.35
Penicillium N	* < 0.35
Cladosporidium	* < 0.35
🔲 A. fumigatus	* < 0.35
Alternaria	* < 0.35
Elm	* < 0.35
Common Ragweed	* < 0.35
Dog Dander	* < 0.35
📃 Bahia Grass	* < 0.35
Meadow Grass	* < 0.35
Cockroach	* < 0.35
Pecan Tree	* < 0.35
Pine, Australian (Beefwood)	* < 0.35
📃 Oak, White	* < 0.35
Pigweed	* < 0.35

Patient 2

	11/14/2019 1714		3/15/2019 1643		10/4/2018 1654		3/20/2018 1512		3/9/2017 0740	
ALLERGEN										
Banana (F92) IgE							0.87 *	•		
Beef Antibody	6.54 *	•	7.64 *	•	12.80 *	•	15.10 *	•	20.40 *	^
Allergen Casein/Co	2.35 *	•	3.27 *	•	4.30 *	•	3.70 *	•		
Chicken Meat (F83)									< 0.35 *	
Allergen Class	Test Deleted *									
Allergen Corn Result							< 0.35 *			
Allergen Oat IgE	5.38 *	•	7.06 *	•	9.94 *	•	12.50 *	•	20.30 *	•
Macadamia Nut (Rf3	1.55 *	•	1.40 *	٠	2.66 *	•	1.55 *	•		
Sesame Seed (F10) IgE	5.77 *	•	7.97 *	•	8.33 *	•	5.74 *	•	11.40 *	•
Tomato (F25) IgE									0.78 *	•
Allergen, Miscellan	Test Deleted *									
Almond (F20) IgE	23.20 *	•	35.70 *	•	41.10 *	•	48.60 *	•	> 100.00 *	•
F018-IgE Brazil Nut	3.99 *	•	3.51 *	•	3.82 *	•	5.29 *	•	5.21 *	•
F202-IgE Cashew Nut	25.00 *	•	26.00 *	*	24.50 *	•	16.80 *	•	1.84 *	•
Cinnamon (F220) IGE									0.40 *	•
Coconut (F36) IgE	1.63 *	•	1.84 *	•	2.04 *	•	3.05 *	•	7.80 *	•
Egg White (F1) IgE	33.70 *	•	47.30 *	٠	57.50 *	•	47.10 *	•		
Egg Yolk (F75) IgE	17.00 *	•					9.53 *	•		
Hazelnut (F17) IgE	6.72 *	•	7.61 *	*	8.27 *	•	4.96 *	•	8.09 *	•
F002-IgE Milk	16.80 *	•	19.60 *	•	25.50 *	•	30.30 *	•		
Orange (F33) IgE									< 0.35 *	
Peanut (F13) IgE	19.10 *	•	41.40 *	•	59.80 *	•	68.70 *	•		
Pecan Nut (F201) IgE	0.77 *	•	0.82 *	•	< 0.35 *		< 0.35 *		< 0.35 *	
Pistachio Nut F203	31.20 *	•	33.60 *	٠	33.50 *	•	21.50 *	•	5.33 *	•
Soybean (F14) IgE	4.00 *	•	5.02 *	•	4.52 *	•	2.81 *	•		
F256-IGE WALNUT	3.68 *	•	1.88 *	•	2.11 *	•	< 0.35 *			
Ovalbumin (F232) IgE	30.00 *	•	33.90 *	•	44.40 *	•	37.40 *	•		



At Panera Bread





Checking Peanut Allergy Status



Skin prick test







Tolerating peanuts All forms Any amount Any time



Paradigm Shift in Food Allergy Management





Effect of filaggrin deficiency on the stratum corneum barrier

OFFICIAL JOURNAL OF

LINECAL REVEWS 17 defidency in human discase

American Academy of Allergy Asthma & Immunology ky in human disease

obial respanse with tissue ation versus protection


MEAL in as a cause of pancreatitis in patients apirin-exacerbated respiratory disease

Gut matters: Microbe-host interactions allergic diseases ROSTRUM

pathquhysiology, and management MARMINANCE OF CERTRICATION CLINICAL MARMAGING In one study, **77%** of patients sensitized to peanut **are not at risk of a severe reaction**

	CCD	PROFILIN	PR-10	LTP	STORAGE PROTEINS
Peanut	MUXF3*	Bet v 2**	Ara h 8	Ara h 9	Ara h 1 Ara h 2 Ara h 3 Ara h 6
Hazelnut			Cora 1	Cora 8	Cora 9 Cora 14
ee Walnut				Jugr 3	Jugr 1
Brazil Nut					Ber e 1
Cashew					Ana o 3

Component Testing



Peanut Components





FIG 1. ROC curves showing the true-positive rate (*Sensitivity*) plotted in function of the false-positive rate (*1-Specificity*) for different cutoff points of the quantified components Ara h 1,2,3,8 and 9 and whole peanut extract. Ara h 2 is the component with the highest accuracy for discriminating between allergy or tolerance to peanut. Analysis included 66 subjects with all available data (27 with peanut allergy and 39 peanut-tolerant).

Nicolaou, N., et al. J Allergy Clin Immunol. 2011;1-2.

Basophil Activation Test (BAT)



Santos and Lack. Clin Transl Allergy (2016)

The Use of BAT in Food Allergy Diagnosis



Food	Author year	Ν	Cut-offs	Sensitivity	Specificity
Peanut	Santos 2014 [15]	N = 104	≥4.78 % CD63+	97.6 %	96.0 %
		Validation population $N = 65$		83.3 %	100 %
	Glaumann 2012 [12]	N = 38	ND	92 %	77 %
	Javaloyes 2012 [16]	N = 26	ND	92 %	95 %
	Ocmant 2009 [17]	N = 75	≥9.1 % CD63+	87 %	94 %
Hazelnut	Brandström 2015 [28]	N = 40	CD-sens > 1.7	100 %	97 %
Egg	Ocmant 2009 [17]	N = 67	≥5 % CD63+	77 %	100 %
Cow's milk	Sato 2010 [19]	N = 50	SI CD203c \geq 1.9	89 %	83 %
Wheat	Tokuda 2009 [<mark>22</mark>]	N = 58	≥14.4 % CD203c+	85 %	77 %
Apple (PFS)	Ebo 2005 [34]	N = 61	Vs sensit. ≥17 % CD63+ Vs NA ≥10 %	Vs sensit. = 88 % Vs NA = 100 %	Vs sensit. = 75 % Vs NA = 100 %
Hazelnut (PFS)	Erdmann 2003 [33]	N = 30	≥6.7 % CD63+	85 %	80 %
Celery (PFS)			≥6.3 % CD63+	85 %	80 %
Carrot (PFS)			≥8.9 % CD63+	85 %	85 %

N number of study participants, PFS pollen-food syndrome, ND not determined, Vs versus, Sensit. sensitised but tolerant, NA non-sensitised non-allergic, SI stimulation index

Santos and Lack. Clin Transl Allergy (2016)

Basophil Activation Test (BAT)

Requires fresh whole blood

5–10% non-responsive rate to IgE-mediated stimulation

Test ordering?

Issues with insurance coverage?



Epitope Testing


with the already existing literature (Radauer et al., 2014).

The resolution of Epitope Mapping eliminates the biological noise associated with sIgE and Component-resolved Diagnostics

Amino Resolution Acids Improvement Peanut sIgE* 2900 1 i ic Component Arah 1 Arah 2 Arah 3 1370 Proteins Arah 2 Arah 2 538 16 Epitopes h2_008 h2 019 15 each 190-Fold Improvement *The allergen Ara h 4 was renamed Ara h 3.02 and the number 4 is not Immunodominant Epitopes available for future peanut allergen designations to avoid confusions

C. Palladino, H. Breiteneder ; Molecular Immunology 100 (2018) 58-70

Testing at the epitope level **improves resolution by 190-fold** by allowing the measurement of epitope level antibody binding (1 Ab: 1 epitope)



Cumulative ≥ 4 mg ≥ 14 mg ≥ 144 mg ≥ 144 mg ≥ 1444 mg ≥ 1444 mg ≥ 1444 mg

If patient is allergic, the test returns the epitope reactivity level and the percentage of patients that tolerated each dose as determined by an OFC.

as determined by a standardized oral food challenge.2-3

Actions and management of food allergies are best managed by a board certified allergist, or those licensed providers with extensive training in food allergy.

references

1. Suarez-Farinas M, Suprun M, Kearney P, Getts R, Grishina G, Hayward C, Luta D, Porter A, Witmer M, du Toit G, Lack G, Chimhrajah R, Galli S, Nadeau K., Sampson H. Accurate and Reproducible Diagnosis of Peanut Allergy Using Epitope Mapping. 15 May 2021. Allergy . https://doi.org/10.111/al14905 2. Data on file, available upon request.

3. Sampson H., Gerth van Wijk R., MD, Bindslev-Jensen C., Sicherer S., Teuber S., Burks W., MD, Dubois A., Beyer K., Eigenmann P., Spergel J., Werfel T., Chinchill V. PRACTALL consensus report, 2012, JACI, 130-6

notes:

DOC # 0I4-Jan2022-Ver.2-MPO_FRT

60%


40%

0%

Tolerated Dose³


280I Sterling Drive Hatfield, PA 19440 l of 2

Benjamin Gerson, M.D. Laboratory Director




Diagnostic and the performance criteria of the test.

CLINICAL CONSIDERATIONS BY LEVEL



PRACTALL Cumulative Tolerated Dose Levels³

Cumulative reactive dose by reactor type





Epitope Testing

Pros

- High Spec, Sens, PPV and NPV
- Provides a probability that a patient can tolerate specific amounts of PN
- Results can be superimposed with OIT dosing schedule / Palforzia ladder

Cons

- Does not predict the severity of reaction
- May result in a false negative if no serum IgE is detectable
- Not recommended for patients on omalizumab or OIT currently
- Requires phlebotomy

Food Allergy Immunotherapy Approaches




Oral IT (OIT)



Sublingual IT (SLIT)



Epicutaneous IT (EPIT)




- Standardized
- Well researched
- Affordable (commercial and Medicaid)
- Easy to prepare/administer
- Great for allergists starting OIT

- Limited to semi solid foods (no liquids)
- Grittiness
- Logistics/pharmacy delays
 - Multiple phone calls
 - Weather delays
- Products not always immediately available for shipping (due to insurance not wanting to pay) depending on when it was last shipped
- Obtaining PA can be a cumbersome






How Does EPIT Work?



Comparison of Food Allergen Immunotherapy


	OIT	SLIT	EPIT
Daily dose (protein)	300-4000 mg	2-7 mg	50-500 μg
Side effects	Gastrointestinal, oral (systemic when associated with fever, URI, exercise)	Oral-pharyngeal (local)	Skin (local)
Desensitization	Large effect	Moderate effect	Ongoing investigation
Long-term tolerance	Variable response	Ongoing investigation	Unknown
Immune modulation	Significant	Present	Present in mice; ongoing investigation in human subjects



Time (months to years)

Kim and Burks. Allergy (2020)

OIT, SLIT, and EPIT



Smeekens and Kulis. Immunol Allergy Clin N Am 40 (2020) 87–95

RESEARCH SUMMARY

Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy

Greenhawt M et al. DOI: 10.1056/NEJMoa2212895

N=244

Placebo

N=118


CLINICAL PROBLEM

Treatments for peanut allergy are not approved for children <4 years of age. However, treatment at younger ages may be more effective than at older ages.


CLINICAL TRIAL

Design: A phase 3, multicenter, double-blind, randomized, placebo-controlled trial compared responses to a peanut food challenge among children 1 to 3 years of age after epicutaneous immunotherapy with a peanut patch or placebo for 12 months.

Intervention: 362 toddlers with peanut allergy elicited by ≤300 mg of peanut protein were assigned, in a 2:1 ratio, to receive an interscapular patch, containing either 250 μ g of peanut protein or a placebo, daily for 12 months. The primary outcome was desensitization to oral peanut-protein challenge, defined as a symptom-eliciting dose of ≥1000 mg of peanut protein (equivalent to approximately 3 to 4 peanuts) for those with baseline responses to >10 mg or ≥300 mg of peanut protein (equivalent to approximately 1 peanut) for those with baseline responses to ≤10 mg.



Treatment Response at 12 mo



Adverse Events during Treatment Period

RESULTS


Efficacy: Significantly more toddlers in the intervention group had a response at 12 months than in the placebo group.

Safety: All the patients who received the peanut patch and 99.2% of those who received placebo had adverse events during treatment, primarily treatment-site reactions in the first 3 months. Serious adverse events occurred in more patients in the intervention group than in the placebo group, including mild-to-moderate anaphylaxis.

LIMITATIONS AND REMAINING QUESTIONS

- Patients with a history of severe anaphylactic response to peanuts were excluded.
- A lack of racial diversity among patients may limit generalizability.
- The appropriate duration of peanut-patch use remains unknown.

Links: Full Article | NEJM Quick Take | Editorial







used daily for 12 months led to peanut desensitization in


Greenhawt M et al. N Engl J Med2023;388:1755-1766

Primary and Sensitivity Analyses of the Primary End Point



Maximum Symptom Severity during Oral Food Challenge





Conclusion: EPIT for 12 months was:

- 1. superior to placebo in desensitizing children to peanuts
- 2. increasing the peanut dose that triggered allergic symptoms

Biologics for treatment of Food Allergy

Omalizumab

- **Most studied** biologic in food allergy
 - Used as an adjunct therapy in multi-food OIT, enabling safe and rapid desensitization (Andorf et al, The lancet. Gastroenterology & hepatology, 2018)
 - Being evaluated in several OIT trials

Ligelizumab (binds to the C ϵ 3 domain of the IgE with higher affinity than omalizumab)

- FDA-granted Breakthrough Therapy for CSU
- Being evaluated in a peanut trial

Biologics for treatment of Food Allergy

Dupilumab (targets IL4Ra, blocks IL-4/IL-13 signaling)

- Two ongoing randomized placebo controlled phase II clinical trials evaluating Dupilumab in food allergy
 - As a monotherapy (NCT03793608)
 - As an adjunct therapy to peanut OIT (NCT03682770)

Anti-IL-5 (mepolizumab, reslizumab, benralizumab)

• No reported trials in food allergy

Therapeutic Agents	Clinical Trials in Food Allergy	References or NCT Number
Anti-IgE		
Omalizumab (Anti-IgE mAb)	Monotherapy for peanut allergy	Savage et al, ¹⁸ 2012 Sampson et al, ¹⁹ 2011 Fiocchi et al, ²⁰ 2019 Leung et al, ⁵⁷ 2003
	Adjunct to peanut, milk or multi-food OIT	Nadeau et al, ²¹ 2011 MacGinnitie et al, ²² 2017 Schneider et al, ²³ 2013 Wood et al, ²⁴ 2016 Andorf et al, ²⁵ 2017; Andorf et al, ²⁶ 2018
A - 41 H 4D		Andorf et al, 2018
Anti-IL 4R Dupilumab (Anti-IL4-R mAb)	Monotherapy for peanut allergy	Phase II (NCT03793608)
	Adjunct to peanut OIT	Phase II (NCT03682770)
Th1 adjuvants		
Glucopyranosyl lipid A (GLA)	Adjunct to peanut SLIT	Phase I (NCT03463135) (Trial has been terminated prematurely)
Anti-TSLP and IL-33		
Etokimab (anti-IL-33 Ab)	Peanut allergy	Phase II (NCT02920021)
DNA vaccines		
ASP0892 (ARA-LAMP-vax)	Peanut allergy	Phase I (NCT03755713) Phase I (NCT02851277)
Modified food allergen proteins		
Encapsulated, recombinant modified peanut proteins Ara h 1, Ara h 2, and Ara h 3 (EMP-123)	Peanut allergy	Wood et al, ⁵⁹ 2013
HAL-MPE1	Peanut allergy	Phase I (NCT02991885)
Anti- Sialic acid binding immunoglobulin like lectin (Siglec-8) Antibody (AK002)	Eosinophilic gastritis and/or eosinophilic gastroenteritis	Phase II (NCT03496571)
Ibrutinib (Bruton's tyrosine kinase inhibitor)	Peanut allergy	Dispenza et al, ⁶⁸ 2018
Targeting the microbiome		
Probiotics	Cow's milk allergy	Berni Canani et al, ⁶¹ 2012; Berni Canani et al, ⁶⁹ 2017 Hol et al, ⁶² 2008 Zhang et al, ⁶³ 2016
Probiotic with peanut oral immunotherapy	Peanut allergy	Tang et al, ⁵⁴ 2015
Fecal microbiota transplantation (FMT)	Peanut allergy	Phase I (NCT02960074)

Investigational Therapies for **Food Allergy**

Albuhairi and Rachid. Immunol Allergy Clin N Am 40 (2020) 87–95



The product is intended to significantly raise a patient's immune threshold through daily use of OMIT toothpaste beyond what has triggered a potentially dangerous allergic reaction via accidental exposure. This additional protection helps relieve the persistent anxiety of peanut allergic individuals toward accidental exposure.



Peanut INT301: Phase 1 Clinical Trial



The Unknowns of Food Immunotherapy

- How long does desensitization from immunotherapy last?
- Without a food challenge, how do determine success?
- Best age to start?
- Is immunotherapy safer than avoidance?
- Do the benefits outweigh the risks?



Thank You

